Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Subscribe To Our Newsletter & Stay Updated